Skip to main content
Erschienen in: Archives of Dermatological Research 10/2018

15.09.2018 | Original Paper

Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers

verfasst von: Laura Cristina Gironi, Enrico Colombo, Barbara Pasini, Roberto Giorgione, Pamela Farinelli, Francesca Zottarelli, Elia Esposto, Elisa Zavattaro, Elias Allara, Paola Ogliara, Marta Betti, Irma Dianzani, Paola Savoia

Erschienen in: Archives of Dermatological Research | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Germline mutations on the CDKN2A gene, the most important known genetic factors associated with cutaneous melanomas (CMs), predispose carriers to multiple primary CMs (MPMs) with higher frequency and younger onset compared to non-carriers. Most of the largest published studies concerning clinical and histological characteristics of CMs with CDKN2A mutation carriers did not specify if the described CMs are first or subsequent to the first, and they used sporadic CMs from non-genotyped patients as controls. We conducted a single-centre observational study to compare clinical and histological CM features of 32 unrelated carriers (MUT) of 5 germline CDKN2A mutations (one of which was never previously described) compared to 100 genotyped wild-type (WT) patients. We stratified the data based on time of diagnosis, anatomical site and histological subtype of CMs, demonstrating several significant unreported differences between the two groups. MUT developed a higher number of dysplastic nevi and MPMs. We proved for the first time that anatomical distribution of CMs in MUT was independent of gender, unlike WTs. MUTs developed in situ and superficial spreading melanomas (SSMs) more frequently, with significantly higher number of SSMs on the head/neck. In MUTs, Breslow thickness was significantly lower for all invasive CMs. When CMs were stratified on the basis of the time of occurrence, statistical significance was maintained only for SSMs subsequent to the first. In WTs, Clark level was significantly higher, and ulceration was more prevalent than in MUTs. Significant differences in ulceration were observed only in SSMs. In nodular CMs, we did not find differences in terms of Breslow thickness or ulceration between WTs and MUTs. In situ CMs developed 10 years earlier in MUTs with respect to WTs, whereas no significant differences were observed in invasive CMs. In contrast to those reported previously by other authors, we did not find a difference in skin phototype.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abdel-Rahman MH, Pilarski R, Cebulla CM et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856–859CrossRef Abdel-Rahman MH, Pilarski R, Cebulla CM et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856–859CrossRef
2.
Zurück zum Zitat Aguilera P, Malvehy J, Carrera C et al (2014) Clinical and histopathological characteristics between familial and sporadic melanoma in Barcelona, Spain. J Clin Exp Dermatol Res 5(5):231PubMedPubMedCentral Aguilera P, Malvehy J, Carrera C et al (2014) Clinical and histopathological characteristics between familial and sporadic melanoma in Barcelona, Spain. J Clin Exp Dermatol Res 5(5):231PubMedPubMedCentral
3.
Zurück zum Zitat AIRTUM Working Group (2016) The contribution of the Italian association of cancer registries (AIRTUM). Epidemiol Prev 40(5Suppl2):28–30 AIRTUM Working Group (2016) The contribution of the Italian association of cancer registries (AIRTUM). Epidemiol Prev 40(5Suppl2):28–30
4.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206CrossRef Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206CrossRef
5.
Zurück zum Zitat Battaglia A (2014) The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol 8:37–47CrossRef Battaglia A (2014) The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol 8:37–47CrossRef
6.
Zurück zum Zitat Beddingfield FC (2003) The melanoma epidemic: res ipsa loquitor. Oncologist 8(5):459–465CrossRef Beddingfield FC (2003) The melanoma epidemic: res ipsa loquitor. Oncologist 8(5):459–465CrossRef
7.
Zurück zum Zitat Bertolotto C (2013) Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) 2013:635203 Bertolotto C (2013) Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) 2013:635203
8.
Zurück zum Zitat Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98CrossRef Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98CrossRef
9.
Zurück zum Zitat Betaille V, de Vries E (2008) Melanoma–Part 1: epidemiology, risk factors, and prevention. BMJ 337:a2249CrossRef Betaille V, de Vries E (2008) Melanoma–Part 1: epidemiology, risk factors, and prevention. BMJ 337:a2249CrossRef
10.
Zurück zum Zitat Betti M, Aspesi A, Biasi A et al (2016) CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett 378(2):120–130CrossRef Betti M, Aspesi A, Biasi A et al (2016) CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett 378(2):120–130CrossRef
11.
Zurück zum Zitat Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132(5):1133–1145CrossRef Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132(5):1133–1145CrossRef
12.
Zurück zum Zitat Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G (2013) BAP1 and cancer. Nat Rev Cancer 13:153–159CrossRef Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G (2013) BAP1 and cancer. Nat Rev Cancer 13:153–159CrossRef
13.
Zurück zum Zitat Chaudru V, Laud K, Avril MF et al (2005) Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14(10):2384–2390CrossRef Chaudru V, Laud K, Avril MF et al (2005) Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14(10):2384–2390CrossRef
14.
Zurück zum Zitat Dummer R, Hauschild A, Guggenheim M et al (2012) Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii86–91CrossRef Dummer R, Hauschild A, Guggenheim M et al (2012) Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii86–91CrossRef
15.
Zurück zum Zitat Fava P, Astrua C, Chiarugi A et al (2015) Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. Dermatology 230(3):256–262CrossRef Fava P, Astrua C, Chiarugi A et al (2015) Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. Dermatology 230(3):256–262CrossRef
16.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRef
17.
Zurück zum Zitat Ferrone CR, Ben Porat L, Panageas KS et al (2005) Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294(13):1647–1654CrossRef Ferrone CR, Ben Porat L, Panageas KS et al (2005) Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294(13):1647–1654CrossRef
18.
Zurück zum Zitat Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline, Update 2012. Eur J Cancer 48(15):2375–2390CrossRef Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline, Update 2012. Eur J Cancer 48(15):2375–2390CrossRef
19.
Zurück zum Zitat Ghiorzo P, Pastorino L, Queirolo P et al (2013) Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 26(2):259–262CrossRef Ghiorzo P, Pastorino L, Queirolo P et al (2013) Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 26(2):259–262CrossRef
20.
Zurück zum Zitat Goldstein AM, Tucker MA (2013) Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 22(4):528–532CrossRef Goldstein AM, Tucker MA (2013) Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev 22(4):528–532CrossRef
21.
Zurück zum Zitat Helgadottir H, Höiom V, Jönsson G et al (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552CrossRef Helgadottir H, Höiom V, Jönsson G et al (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552CrossRef
22.
Zurück zum Zitat Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961CrossRef Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961CrossRef
23.
Zurück zum Zitat Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959CrossRef Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959CrossRef
24.
Zurück zum Zitat Leachman SA, Lucero OM, Sampson JE et al (2017) Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36(1):77–90CrossRef Leachman SA, Lucero OM, Sampson JE et al (2017) Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36(1):77–90CrossRef
25.
Zurück zum Zitat Måsbäck A, Olsson H, Westerdahl J et al (2002) Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families. Melanoma Res 12(6):549–557CrossRef Måsbäck A, Olsson H, Westerdahl J et al (2002) Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families. Melanoma Res 12(6):549–557CrossRef
26.
Zurück zum Zitat Miller PJ, Duraisamy S, Newell JA et al (2011) Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 32(8):900–911CrossRef Miller PJ, Duraisamy S, Newell JA et al (2011) Classifying variants of CDKN2A using computational and laboratory studies. Hum Mutat 32(8):900–911CrossRef
27.
Zurück zum Zitat Pastorino L, Bonelli L, Ghiorzo P et al (2008) CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 21(6):700–709CrossRef Pastorino L, Bonelli L, Ghiorzo P et al (2008) CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 21(6):700–709CrossRef
28.
Zurück zum Zitat Pellegrini C, Maturo MG, Martorelli C et al (2017) Characterization of melanoma susceptibility genes in high-risk patients from Central Italy. Melanoma Res 27(3):258–267CrossRef Pellegrini C, Maturo MG, Martorelli C et al (2017) Characterization of melanoma susceptibility genes in high-risk patients from Central Italy. Melanoma Res 27(3):258–267CrossRef
29.
Zurück zum Zitat Queirolo P, Acquati M, Kirkwood JM et al (2005) Update: current management issues in malignant melanoma. Melanoma Res 15(5):319–324CrossRef Queirolo P, Acquati M, Kirkwood JM et al (2005) Update: current management issues in malignant melanoma. Melanoma Res 15(5):319–324CrossRef
30.
Zurück zum Zitat Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46:478–481CrossRef Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46:478–481CrossRef
31.
Zurück zum Zitat Sargen MR, Kanetsky PA, Newton-Bishop J et al (2015) Histologic features of melanoma associated with CDKN2A genotype. J Am Acad Dermatol 72(3):496–507.e7CrossRef Sargen MR, Kanetsky PA, Newton-Bishop J et al (2015) Histologic features of melanoma associated with CDKN2A genotype. J Am Acad Dermatol 72(3):496–507.e7CrossRef
32.
Zurück zum Zitat Savoia P, Osella-Abate S, Deboli T et al (2012) Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study. J Eur Acad Dermatol Venereol 26(7):882–888CrossRef Savoia P, Osella-Abate S, Deboli T et al (2012) Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study. J Eur Acad Dermatol Venereol 26(7):882–888CrossRef
33.
Zurück zum Zitat Shi J, Yang XR, Ballew B et al (2014) Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 46:482–486CrossRef Shi J, Yang XR, Ballew B et al (2014) Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 46:482–486CrossRef
34.
Zurück zum Zitat Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (2016) Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 74(3):395–407; quiz 408 – 10CrossRef Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (2016) Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 74(3):395–407; quiz 408 – 10CrossRef
35.
Zurück zum Zitat Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (2016) Hereditary melanoma: Update on syndromes and management: emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol 74(3):411–420; quiz 421-2CrossRef Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (2016) Hereditary melanoma: Update on syndromes and management: emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol 74(3):411–420; quiz 421-2CrossRef
36.
Zurück zum Zitat Taylor NJ, Handorf EA, Mitra N et al (2016) Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families. J Invest Dermatol 136(5):1066–1069CrossRef Taylor NJ, Handorf EA, Mitra N et al (2016) Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families. J Invest Dermatol 136(5):1066–1069CrossRef
37.
Zurück zum Zitat Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG (2000) Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 136:1118–1122CrossRef Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG (2000) Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 136:1118–1122CrossRef
38.
Zurück zum Zitat Tucker MA (2009) Melanoma epidemiology. Hematol Oncol Clin North Am 23(3):383–395, viiCrossRef Tucker MA (2009) Melanoma epidemiology. Hematol Oncol Clin North Am 23(3):383–395, viiCrossRef
39.
Zurück zum Zitat Van der Rhee JI, Krijnen P, Gruis NA et al (2011) Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol 65(2):281–288CrossRef Van der Rhee JI, Krijnen P, Gruis NA et al (2011) Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol 65(2):281–288CrossRef
40.
Zurück zum Zitat Wadt KA, Aoude LG, Johansson P et al (2015) A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88(3):267–272CrossRef Wadt KA, Aoude LG, Johansson P et al (2015) A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88(3):267–272CrossRef
Metadaten
Titel
Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers
verfasst von
Laura Cristina Gironi
Enrico Colombo
Barbara Pasini
Roberto Giorgione
Pamela Farinelli
Francesca Zottarelli
Elia Esposto
Elisa Zavattaro
Elias Allara
Paola Ogliara
Marta Betti
Irma Dianzani
Paola Savoia
Publikationsdatum
15.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 10/2018
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-018-1866-0

Weitere Artikel der Ausgabe 10/2018

Archives of Dermatological Research 10/2018 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.